• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by scPharmaceuticals Inc.

    10/7/25 4:11:27 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPH alert in real time by email
    S-8 POS 1 d932608ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on October 7, 2025

    Registration No. 333-285933

    Registration No. 333-277892

    Registration No. 333-270757

    Registration No. 333-270758

    Registration No. 333-263762

    Registration No. 333-254636

    Registration No. 333-237361

    Registration No. 333-229122

    Registration No. 333-227071

    Registration No. 333-221677

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO:

    FORM S-8 REGISTRATION STATEMENT NO. 333-285933

    FORM S-8 REGISTRATION STATEMENT NO. 333-277892

    FORM S-8 REGISTRATION STATEMENT NO. 333-270757

    FORM S-8 REGISTRATION STATEMENT NO. 333-270758

    FORM S-8 REGISTRATION STATEMENT NO. 333-263762

    FORM S-8 REGISTRATION STATEMENT NO. 333-254636

    FORM S-8 REGISTRATION STATEMENT NO. 333-237361

    FORM S-8 REGISTRATION STATEMENT NO. 333-229122

    FORM S-8 REGISTRATION STATEMENT NO. 333-227071

    FORM S-8 REGISTRATION STATEMENT NO. 333-221677

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    SCPHARMACEUTICALS INC.

    (Exact Name of Registrant As Specified In Its Charter)

     

     

     

    Delaware   46-5184075

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    25 Mall Road, Suite 203

    Burlington, Massachusetts, 01803

    (617) 517-0730

    (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

    scPharmaceuticals Inc. 2014 Stock

    Incentive Plan

    scPharmaceuticals Inc. 2017 Stock Option

    and Incentive Plan

    scPharmaceuticals Inc. 2017 Employee

    Stock Purchase Plan

    scPharmaceuticals Inc. 2023 Employment

    Inducement Award Plan

    (Full Title of the Plans)

     

     

    Michael E. Castagna

    Chief Executive Officer

    MannKind Corporation

    1 Casper Street

    Danbury, Connecticut 06810

    (818) 661-5000

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    David Thomson, Esq.

    MannKind Corporation

    1 Casper Street

    Danbury, Connecticut 06810

    (818) 661-5000

     

    Barbara Borden, Esq.

    Rowook Park, Esq.

    Asa M. Henin, Esq.

    Cooley LLP

    10265 Science Center Drive

    San Diego, California 92121

    (858) 550-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

      ☐    Accelerated filer   ☐

    Non-accelerated filer

      ☒    Smaller reporting company   ☒
         Emerging Growth Company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    These post-effective amendments (the “Post-Effective Amendments”) relate to the following Registration Statements on Form S-8 (each a “Registration Statement” and collectively, the “Registration Statements”), filed with the Securities and Exchange Commission (the “SEC”) by scPharmaceuticals Inc., a Delaware corporation (the “Registrant”) and is being filed to deregister any and all securities that remain unsold or otherwise unissued as of the date hereunder under such Registration Statements:

     

      •  

    Registration Statement on Form S-8 (No. 333-285933), registering (i) 205,000 shares of the Registrant’s common stock, par value $0.0001 per share (“Common Stock”), issuable under the scPharmaceuticals Inc. 2017 Employee Stock Purchase Plan (the “ESPP”) and (ii) 2,003,827 shares of Common Stock issuable under the scPharmaceuticals Inc. 2017 Stock Option and Incentive Plan (the “2017 Incentive Plan”), filed with the SEC on March 19, 2025;

     

      •  

    Registration Statement on Form S-8 (No. 333-277892), registering (i) 205,000 shares of the Registrant’s Common Stock, issuable under the ESPP and (ii) 1,438,740 shares of Common Stock issuable under the 2017 Incentive Plan, filed with the SEC on March 13, 2024;

     

      •  

    Registration Statement on Form S-8 (No. 333-270757), registering 205,000 shares of the Registrant’s Common Stock, issuable under the ESPP and (ii) 1,370,316 shares of Common Stock issuable under the 2017 Incentive Plan, filed with the SEC on March 22, 2023;

     

      •  

    Registration Statement on Form S-8 (No. 333-270758), registering 500,000 shares of the Registrant’s Common Stock, issuable under the scPharmaceuticals Inc. 2023 Employment Inducement Award Plan, filed with the SEC on March 22, 2023;

     

      •  

    Registration Statement on Form S-8 (No. 333-263762), registering (i) 205,000 shares of the Registrant’s Common Stock, issuable under the ESPP and (ii) 1,094,668 shares of Common Stock issuable under the 2017 Incentive Plan, filed with the SEC on March 22, 2022;

     

      •  

    Registration Statement on Form S-8 (No. 333-254636), registering (i) 205,000 shares of the Registrant’s Common Stock, issuable under the ESPP and (ii) 1,093,038 shares of Common Stock issuable under the 2017 Incentive Plan, filed with the SEC on March 23, 2021;

     

      •  

    Registration Statement on Form S-8 (No. 333-237361), registering (i) 194,189 shares of the Registrant’s Common Stock, issuable under the ESPP and (ii) 776,758 shares of Common Stock issuable under the 2017 Incentive Plan, filed with the SEC on March 24, 2020;

     

      •  

    Registration Statement on Form S-8 (No. 333-229122), registering (i) 185,693 shares of the Registrant’s Common Stock, issuable under the ESPP and (ii) 742,772 shares of Common Stock issuable under the 2017 Incentive Plan, filed with the SEC on January 3, 2019;

     

      •  

    Registration Statement on Form S-8 (No. 333-227071), registering (i) 205,000 shares of the Registrant’s Common Stock, issuable under the ESPP and (ii) 741,389 shares of Common Stock issuable under the 2017 Incentive Plan, filed with the SEC on August 28, 2018; and

     

      •  

    Registration Statement on Form S-8 (No. 333-221677), registering (i) 205,000 shares of the Registrant’s Common Stock, issuable under the ESPP, (ii) 1,430,000 shares of Common Stock issuable under the 2017 Incentive Plan, filed with the SEC on November 20, 2017 and (iii) 1,165,453 shares of Common Stock issuable under the scPharmaceuticals Inc. 2014 Stock Incentive Plan.


    On August 24, 2025, the Registrant entered into that certain Agreement and Plan of Merger (the “Merger Agreement”) with MannKind Corporation, a Delaware corporation (“Parent”), and Seacoast Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, on October 7, 2025, Merger Sub merged with and into the Registrant with the Registrant surviving the merger as a wholly-owned subsidiary of Parent (the “Merger”).

    As a result of the Merger, the Registrant has terminated any and all of the offerings and sales of the Registrant’s securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance under the Registration Statements but remain unsold at the termination of the offerings, the Registrant hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof, and each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statements.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments No. 1 to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Danbury, State of Connecticut, on October 7, 2025.

     

    scPharmaceuticals Inc.
    By:  

    /s/ Michael E. Castagna

    Name:   Michael E. Castagna
    Title:   President

    No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

    Get the next $SCPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCPH

    DatePrice TargetRatingAnalyst
    9/7/2023$20.00Buy
    Craig Hallum
    12/1/2022$25.00Outperform
    Cowen
    10/21/2022$14.00Buy
    Jefferies
    10/11/2022$11.00Mkt Perform → Outperform
    SVB Leerink
    8/2/2022$10.00Buy
    Maxim Group
    9/9/2021$6.00Market Perform
    SVB Leerink
    More analyst ratings

    $SCPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FUROSCIX issued to SCPHARMACEUTICALS INC

    Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form

    10/11/22 1:54:57 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

    Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals' 90 trading day VWAP, and total consideration of up to $6.35 per share represents up to a 31% premium to scPharmaceuticals' closing price on August 22, 2025Strengthens organization by integrating scPharmaceuticals

    8/25/25 7:30:00 AM ET
    $MNKD
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111

    BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111 formulation is the subject of a supplemental NDA expected to be filed by the Company this quarter. The five patents, once issued, will join four additional patents owned by the Company that cover the SCP-111 formulation. "These allowances are vital developments

    8/14/25 8:30:46 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

    Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $40.8 million as of June 30, 2025 Investor conference call and webcast today, Thursday, August 7th, at 4:30pm ET BURLINGTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat

    8/7/25 4:01:50 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schaeffer Leonard D closing all direct ownership in the company (SEC Form 4)

    4 - scPharmaceuticals Inc. (0001604950) (Issuer)

    10/7/25 4:30:20 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO and Treasurer Nokes Rachael returned 125,675 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - scPharmaceuticals Inc. (0001604950) (Issuer)

    10/7/25 4:30:10 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Baylor-Henry Minnie

    4 - scPharmaceuticals Inc. (0001604950) (Issuer)

    10/7/25 4:30:13 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on scPharmaceuticals with a new price target

    Craig Hallum initiated coverage of scPharmaceuticals with a rating of Buy and set a new price target of $20.00

    9/7/23 9:06:27 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cowen initiated coverage on scPharmaceuticals with a new price target

    Cowen initiated coverage of scPharmaceuticals with a rating of Outperform and set a new price target of $25.00

    12/1/22 7:54:00 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on scPharmaceuticals with a new price target

    Jefferies resumed coverage of scPharmaceuticals with a rating of Buy and set a new price target of $14.00

    10/21/22 7:40:23 AM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by scPharmaceuticals Inc.

    SCHEDULE 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

    10/8/25 5:02:38 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by scPharmaceuticals Inc.

    S-8 POS - scPharmaceuticals Inc. (0001604950) (Filer)

    10/7/25 4:22:03 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by scPharmaceuticals Inc.

    S-8 POS - scPharmaceuticals Inc. (0001604950) (Filer)

    10/7/25 4:20:32 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Orbimed Advisors Llc bought $2,000,000 worth of shares (500,000 units at $4.00) (SEC Form 4)

    4 - scPharmaceuticals Inc. (0001604950) (Issuer)

    8/15/24 4:51:14 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    Leadership Updates

    Live Leadership Updates

    View All

    Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

    NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

    3/1/22 4:05:00 PM ET
    $APYX
    $LNTH
    $PRTK
    Medical/Dental Instruments
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Biotechnology: Pharmaceutical Preparations

    $SCPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

    SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

    11/15/24 4:06:50 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

    SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

    11/14/24 5:48:35 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

    SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

    11/14/24 3:58:44 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPH
    Financials

    Live finance-specific insights

    View All

    MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

    Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals' 90 trading day VWAP, and total consideration of up to $6.35 per share represents up to a 31% premium to scPharmaceuticals' closing price on August 22, 2025Strengthens organization by integrating scPharmaceuticals

    8/25/25 7:30:00 AM ET
    $MNKD
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

    Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $40.8 million as of June 30, 2025 Investor conference call and webcast today, Thursday, August 7th, at 4:30pm ET BURLINGTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat

    8/7/25 4:01:50 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

    BURLINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 7, 2025, to discuss the financial results for the second quarter 2025 and provide a business update. A link to the live webcast can be found here. Participants should dial (800) 715-9871 (toll-free) or (646) 307-1963 (toll) and use the passcode 4965353 The live webcast and replay of the conference call can be accessed here or under "News & Events" in the I

    7/31/25 4:01:00 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care